Indivior ( (GB:INDV) ) just unveiled an announcement.
Indivior PLC announced significant changes to its Board of Directors, including a reduction in board size to seven directors and the commencement of a search for a new Independent Non-Executive Director. These changes align with the company’s strategic shift to a US primary listing and are part of an amended agreement with Oaktree Capital Management. The company also announced leadership changes within its committees and the discontinuation of its Operational Committee, reflecting a strategic realignment to enhance its governance and operational focus.
More about Indivior
Indivior is a global pharmaceutical company focused on developing medicines to treat substance use disorders (SUD), with a vision to provide evidence-based treatment for these chronic conditions worldwide. Headquartered in Richmond, VA, Indivior employs over 1,000 individuals and offers its products in over 30 countries.
YTD Price Performance: -31.69%
Average Trading Volume: 318,590
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: £870.5M
See more insights into INDV stock on TipRanks’ Stock Analysis page.